BioCentury
ARTICLE | Clinical News

Immune Design reports Phase I OS data for CMB305 in STS

May 4, 2018 3:42 PM UTC

In March, Immune Design Corp. (NASDAQ:IMDZ) reported data from 25 patients with cancer/testis antigen 1B (NY-ESO-1; CTAG1B)-positive soft tissue sarcoma (STS) in an open-label, U.S. Phase I trial showing that CMB305 as monotherapy led to a median overall survival (OS) of 23.7 months. Median OS has not yet been reached in the subset of 14 patients with synovial sarcoma. According to Immune Design, the median OS for approved second line and later chemotherapeutic agents is 12.4-13.5 months for STS patients and 11.7 months for synovial sarcoma patients.

Immune Design plans to start a Phase III trial of CMB305 as monotherapy to treat synovial sarcoma in mid-2018...

BCIQ Company Profiles

Immune Design Corp.